Exelixis Inc Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31)
Exelixis Inc (EXEL) reported Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) of $319.00 thousand for the 12-month period ending 2017-12-29, per its 10-K filed 2018-02-26.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAggregateLosses · last filed 2018-02-26
- Exelixis Inc available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for fiscal 2017 was $319.00K, a 0.00% change from fiscal 2016.
- Exelixis Inc available-for-sale securities, continuous unrealized loss position, less than 12 months, aggregate loss (deprecated 2018-01-31) for fiscal 2016 was $319.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, Less than 12 Months, Aggregate Loss (Deprecated 2018-01-31) 12 month |
|---|---|
| 2017-12-29 | $319.00K 10-K · filed 2018-02-26 |
| 2016-12-30 | $319.00K 10-K · filed 2018-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |